Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.

@article{Kraft1990EffectsOV,
  title={Effects of verapamil on anthracycline-induced cardiomyopathy: preliminary results of a prospective multicenter trial.},
  author={J. Kraft and W. Grille and M. Appelt and D. Hossfeld and M. Eichelbaum and B. Koslowski and K. Quabeck and R. Kuse and T. Büchner and W. Hiddemann},
  journal={Haematology and blood transfusion},
  year={1990},
  volume={33},
  pages={
          566-70
        }
}
Previous investigations in animals and one retrospective study in man suggest that verapamil can prevent anthracycline-induced cardiomyopathy. In the following study, patients with acute myeloid leukemia (AML) treated with double induction and consolidation chemotherapy (AML COOP study 1986, [3]) were randomized in a group with and without accompanying low-dose oral verapamil treatment. Since July 1986, 64 patients have been included. Thirty patients have been evaluated for pre- and… Expand
12 Citations
Anthracycline cardiotoxicity
  • 166
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
  • 246
Cardioprotective interventions for cancer patients receiving anthracyclines.
  • 173
Heart transplantation in a patient with multiple sclerosis and mitoxantrone-induced cardiomyopathy.
  • 13
Anthracycline Chemotherapy and Cardiotoxicity
  • 311
  • PDF
Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers
  • 35
Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity
  • 111
Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.
  • 32
  • PDF
Anthracycline-induced cardiotoxicity during and after treatment for childhood cancer : long-term risk, risk factors and prevention
  • Highly Influenced
  • PDF
...
1
2
...

References

SHOWING 1-8 OF 8 REFERENCES